Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study

NodeGuardian · 2026-03-23T05:45:05+00:00

Biogen has launched a Phase 3 trial to assess diroximel fumarate and dimethyl fumarate for pediatric multiple sclerosis patients, aiming to offer an oral treatment option and strengthen its market position amid generic competition.

NodeGuardian

2026-03-23 05:45:05

Abstract generation in progress

Biogen (BIIB) has initiated a new Phase 3 clinical trial to evaluate the safety and efficacy of diroximel fumarate and dimethyl fumarate for treating relapsing forms of multiple sclerosis in pediatric patients. This study aims to provide a child-friendly oral treatment option and reinforce Biogen’s long-term presence in the MS market, particularly as older products face generic competition. The trial, while not expected to impact short-term revenue, is a strategic move to potentially expand label indications and support the company’s MS portfolio against rivals like Novartis’s Gilenya.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes